Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Radiopharm Theranostics Limited ( (AU:RAD) ) just unveiled an announcement.
Radiopharm Theranostics has disclosed a change in the interests of director Paul Hopper, who was issued 18,142,000 unlisted options as approved by shareholders at the company’s Annual General Meeting on 20 November 2025. Following this non-cash issuance, Hopper’s direct holdings increased to 53,900,000 shares and 53,642,000 options, with his total direct and indirect option interests rising to 62,659,518, signalling continued alignment of the director’s incentives with shareholder interests and the company’s long-term strategic objectives.
The most recent analyst rating on (AU:RAD) stock is a Buy with a A$0.06 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited (ASX: RAD) is an Australian-listed company operating in the radiopharmaceutical and theranostics sector. It focuses on developing and commercialising targeted diagnostic and therapeutic products that use radioactive agents for cancer and other serious diseases, serving healthcare providers and patients in the precision oncology market.
Average Trading Volume: 12,079,242
Technical Sentiment Signal: Buy
Current Market Cap: A$99.24M
Learn more about RAD stock on TipRanks’ Stock Analysis page.